Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 30;15(15):3887. doi: 10.3390/cancers15153887

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Current therapeutic options for advanced, unresectable, metastatic SyS. After local therapies and front line anthracycline and ifosfamide-based chemotherapy (CHT) [4], patients showing disease relapse undergo second line CHT with decreased ORR and OS [25,30,31]. Immunological therapies under evaluation in phase I/II clinical trials show limited results for ICI in SyS patients, but improved outcomes can derive from the use of tumor immune microenvironment biomarkers for the selection of patients more likely to respond to ICI-based therapies [50,51,62,63]. Higher ORR can be observed in HLA-A2 positive patients receiving TCR-engineered T-cells recognizing cancer/testis antigen (CTA) peptides [66,68,69,70,74,75,76,79] (created with Biorender.com accessed on 25 July 2023).